Crescent Biopharma, Inc.
CBIO
$12.96
-$0.14-1.07%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 152.65M | ||||
| Total Receivables | -- | ||||
| Inventory | -- | ||||
| Prepaid Expenses | 1.58M | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | 154.23M | ||||
|
|
|||||
| Total Current Assets | 154.23M | ||||
| Net Property, Plant & Equipment | 1.80M | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | 1.41M | ||||
| Total Assets | 157.43M | ||||
|
|
|||||
| Total Accounts Payable | 1.65M | ||||
| Total Accrued Expenses | 12.79M | ||||
| Short-term Debt | -- | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | 211.00K | ||||
| Total Finance Division Other Current Liabilities | 2.10M | ||||
| Total Other Current Liabilities | 2.10M | ||||
| Total Current Liabilities | 16.75M | ||||
|
|
|||||
| Total Current Liabilities | 16.75M | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -- | ||||
| Capital Leases | 1.43M | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | 18.18M | ||||
|
|
|||||
| Common Stock & APIC | 194.06M | ||||
| Retained Earnings | -54.81M | ||||
| Treasury Stock & Other | -- | ||||
| Total Common Equity | 139.25M | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | -- | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | -- | ||||
|
|
|||||
| Total Common Equity | 139.25M | ||||
| Total Preferred Equity | -- | ||||
| Total Minority Interest | -- | ||||
| Total Equity | 139.25M | ||||
|
|
|||||